Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO(TM) to Australia and New Zealand

Executive Summary

• Profound Medical entered an exclusive distribution and supply agreement with Getz Healthcare for its TULSA‑PRO® system in Australia and New Zealand.
• The partnership gives Profound access to a new geographic market, potentially expanding revenue streams for its AI‑powered MRI‑guided prostate therapy platform.
• Management highlighted the deal as a strategic step toward further expansion across the Asia‑Pacific region.

Key Details

• Agreement Scope: Exclusive distribution and supply of the TULSA‑PRO® system in Australia and New Zealand.
• Partner: Getz Healthcare, a leading medical device distributor in the Asia‑Pacific with ISO 9001:2015 certification and a network of 23 offices/centres.
• Product Covered: TULSA‑PRO® – AI‑powered, MR‑guided robotic system for incision‑free prostate ablation (CE marked, Health Canada approved, FDA 510(k) cleared).
• Strategic Rationale: Provides Profound a foothold in the Australasia market where prostate cancer is the most common male cancer; supports broader Asia‑Pacific expansion plans.
• Commercial Impact: Expected to generate additional sales volume and diversify revenue beyond North America; no specific financial terms disclosed.
• Operational Note: Profound continues to deploy its own direct sales team in North America while leveraging selective distribution partners internationally.

Notable Quotes

• “We are excited to gain access to this significant market for TULSA‑PRO,” – Arun Menawat, CEO & Chairman, Profound Medical Corp.
• “Our exclusive partnership with Profound Medical marks a significant step in advancing precision prostate care across Australia and New Zealand,” – Derek Foltin, Managing Director, Getz Healthcare ANZ.